RDInvesting Provides Investors with Free In-Depth Equity Reports on CLSN, IRWD, KIOR and OREX


Follow this company

Companies Mentioned

NASDAQ:CLSN / NASDAQ:IRWD / NASDAQ:KIOR / NASDAQ:OREX
01/13/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Celsion Corporation (NASDAQ: CLSN) shares increased 12.84 percent to close at $4.57 a share Friday. The stock traded between $4.22 and $4.74 on volume of 1.20 million shares traded. Analysts at H.C. Wainwright have recently initiated coverage on the company with a “buy” rating and a price target of $8.00.

Find out more about Celsion including full access to the free equity report at:     
www.RDInvesting.com/CLSN

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares gained 4.44 percent to close at $12.94 a share Friday. The stock traded between $12.50 and $13.48 on volume of 3.62 million shares traded. Analysts at BMO Capital have recently upgraded the company’s rating to "outperform" from "market perform". Shares of Ironwood Pharmaceuticals have fallen approximately 12.0 percent in the past year.

Find out more about Ironwood Pharmaceuticals including full access to the free equity report at:       
www.RDInvesting.com/IRWD

KiOR Inc. (NASDAQ: KIOR) shares declined 4.85 percent to close at $1.57 a share Friday. The stock traded between $1.46 and $1.60 on volume of 809,573 shares traded. Analysts at Raymond James have recently downgraded the company’s rating to "market perform" from "outperform". Shares of KiOR have fallen approximately 75.0 percent in the past year.

Find out more about KiOR including full access to the free equity report at:       
www.RDInvesting.com/KIOR

Orexigen Therapeutics, Inc. (NASDAQ: OREX) shares increased 1.44 percent to close at $6.36 a share Friday. The stock traded between $6.15 and $6.45 on volume of 2.97 million shares traded. Analysts at WallachBeth have recently initiated coverage on the company with a "buy" rating and a price target of $9.00. Shares of Orexigen Therapeutics have gained approximately 5.0 percent in the past year.

Find out more about Orexigen Therapeutics including full access to the free equity report at:     
www.RDInvesting.com/OREX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:         
Research Driven Investing        
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *